How long does Belsomra (suvorexant) take to work?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How Long Does Belsomra Take to Work?

Belsomra (suvorexant) should be taken within 30 minutes of going to bed, and patients should only take it when they can remain in bed for at least 7 hours before needing to be active again. 1

Onset of Action

Pharmacokinetic Profile

  • Peak plasma concentration occurs approximately 2 hours after ingestion 2
  • The median time to reach maximum observed concentration ranges from 1.5 to 4.0 hours across different doses 3
  • The medication has an apparent terminal half-life of 7.7 to 14.5 hours 3

Clinical Efficacy Timeline

Night 1/Week 1 Effects:

  • Suvorexant demonstrates efficacy as early as the first night of treatment based on polysomnographic (objective sleep study) measurements 4
  • At Week 1, patients showed statistically significant improvements in both sleep onset and sleep maintenance compared to placebo 5
  • The American Academy of Sleep Medicine guidelines note that effects at night 1 and week 1 were generally consistent with later time points 4

Sustained Effects:

  • Efficacy is maintained at Month 1 and Month 3 of treatment 4, 5
  • The medication shows clinically significant reductions in wake after sleep onset at both 10 mg and 20 mg dosages throughout the treatment period 4

Important Administration Considerations

Timing and Food Interactions

  • Take within 30 minutes of going to bed 1
  • Belsomra may be taken with or without meals, but may take longer to work if taken with or right after meals 1
  • Do not take if alcohol was consumed that evening or before bed 1

Safety Window

  • Patients must be able to stay in bed for a full night (at least 7 hours) before being active again 1
  • This is critical because the medication's half-life of approximately 12 hours means residual effects can persist into the next morning 2

Dose-Dependent Considerations

Sleep Onset (Latency) Effects:

  • At 10 mg and 15/20 mg doses: minimal improvements in sleep latency that may not meet clinical significance thresholds 4
  • At 20 mg dose: clinically significant reduction in sleep latency of 22.3 minutes compared to placebo 4

Sleep Maintenance Effects:

  • Both 10 mg and 20 mg doses show clinically significant reductions in wake after sleep onset from the first night of treatment 4
  • This suggests the medication may work more effectively for sleep maintenance than sleep onset, particularly at lower doses 4

Clinical Pitfalls

  • Next-morning impairment: Due to the 12-hour half-life, patients may experience decreased awareness and alertness the morning after taking Belsomra, particularly at the 20 mg dose 1, 2
  • Driving impairment: Patients using 20 mg should be cautioned against next-day driving 9 hours after dosing 1
  • If insomnia does not improve within 7 to 10 days, contact your healthcare provider, as this may indicate another underlying condition 1

References

Research

Suvorexant: scientifically interesting, utility uncertain.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2017

Guideline

clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.